Trial Profile

A Pilot, Proof of Concept, Placebo-controlled Trial of Candesartan as an Adjunctive Treatment for Bipolar Depression

Status: Withdrawn prior to enrolment

Phase of Trial: Phase 0

Latest Information Update: 28 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Candesartan cilexetil (Primary)
Indications Bipolar depression; Bipolar I disorders; Bipolar II disorders
Focus Proof of concept; Therapeutic Use

Most Recent Events

19 Apr 2022 Status changed from recruiting to withdrawn prior to enrolment since lack of funds. In addition, the PI is moving to a different institution and it would not be feasible to proceed with the study under these circumstances.
29 Sep 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.
29 Sep 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com